1 안정열1, "한국인 본태성혈소판혈증 환자에서 JAK2V617F 유전자 변이" 대한진단검사의학회 27 (27): 77-82, 2007
2 Jones AV, "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders" 106 : 2162-2168, 2005
3 Butcher CM, "Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients" 22 : 870-873, 2008
4 Percy MJ, "The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels" 92 : 1607-1614, 2007
5 Vardiman JW, "The World Health Organization (WHO) classification of the myeloid neoplasms" 100 : 2292-2302, 2002
6 Jones AV, "The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms" 115 : 4517-4523, 2010
7 Pardanani A, "The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients" 24 : 110-114, 2010
8 Barosi G, "The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia" 104 : 730-737, 1999
9 Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders" 111 : 1686-1689, 2008
10 Saharinen P, "Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain" 20 : 3387-3395, 2000
1 안정열1, "한국인 본태성혈소판혈증 환자에서 JAK2V617F 유전자 변이" 대한진단검사의학회 27 (27): 77-82, 2007
2 Jones AV, "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders" 106 : 2162-2168, 2005
3 Butcher CM, "Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients" 22 : 870-873, 2008
4 Percy MJ, "The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels" 92 : 1607-1614, 2007
5 Vardiman JW, "The World Health Organization (WHO) classification of the myeloid neoplasms" 100 : 2292-2302, 2002
6 Jones AV, "The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms" 115 : 4517-4523, 2010
7 Pardanani A, "The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients" 24 : 110-114, 2010
8 Barosi G, "The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia" 104 : 730-737, 1999
9 Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders" 111 : 1686-1689, 2008
10 Saharinen P, "Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain" 20 : 3387-3395, 2000
11 Watanabe S, "Roles of the JAK-STAT system in signal transduction via cytokine receptors" 6 : 587-596, 1996
12 Levine RL, "Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders" 7 : 673-683, 2007
13 Michiels JJ, "Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group" 23 : 339-347, 1997
14 Kurzrock R, "Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics" 138 : 819-830, 2003
15 Tefferi A, "Oncogenes in myeloproliferative disorders" 6 : 550-566, 2007
16 "NCBI Single Nucleotide Polymorphism"
17 Delhommeau F, "Molecular aspects of myeloproliferative neoplasms" 91 : 165-173, 2010
18 Scott LM, "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis" 245 : 459-468, 2007
19 Quentmeier H, "JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders" 20 : 471-476, 2006
20 Barosi G, "JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis" 110 : 4030-4036, 2007
21 Bousquet M, "Frequent detection of the JAK2 V617F mutation in bone ma-rrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations" 37 : 1458-1464, 2006
22 Aplenc R, "Differential bone marrow aspirate DNA yields from commercial extraction kits" 16 : 1865-1866, 2002
23 Soo-Mee Bang, "Diagnostic Usefulness of the Janus Kinase 2 Mutation in nonBCR/ABL Myeloproliferative Disorders" 대한내과학회 21 (21): 219-224, 2006
24 Horn T, "Detection of the activating JAK2 V617F mutation in paraffinembedded trephine bone marrow biopsies of patients with chronic myeoproliferative diseases" 8 : 299-304, 2006
25 Lay M, "Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis" 8 : 330-334, 2006
26 Schnittger S, "Detection of JAK2 exon 12 mutations in 15 patients with JAK2 V617F negative polycythemia vera" 94 : 414-418, 2009
27 Speletas M, "Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders" 31 : 1053-1062, 2007
28 Saltzman A, "Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue" 246 : 627-633, 1998
29 Tefferi A, "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms" 22 : 14-22, 2008
30 Levine RL, "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis" 7 : 387-397, 2005
31 Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders" 365 : 1054-1061, 2005
32 Tan AY, "A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation" 127 : 977-981, 2007
33 Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders" 352 : 1779-1790, 2005